US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights:

US Breast Cancer Drug Market Opportunity: US$ 20 Billion
US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment
US Breast Cancer Marketed Drugs: 42 Drugs
US Breast Cancer Drug Clinical Pipeline: 317 Drugs
Dosage and Pricing Insight for Preventive and Treatment Drugs
US Breast Cancer Drug Market Dynamics

Breast cancer is the most commonly diagnosed cancer in American women. Breast cancer occurring in a woman under 40 is not a typical condition anymore. Changing lifestyle with numerous other factors like early menarche, late age at first childbirth, late menopause and prolonged exposure to endogenous oestrogens are surging the breast cancer drug market at a high rate. Also, short breast-feeding timeframe, rising of obesity in women after menopause, increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills which causes increased levels of oestrogen are boosting the breast cancer drug market to its peak.

Various breast cancer therapeutics have come into existence like hormone drugs, chemotherapy drugs and targeted drugs. With advancements in drug delivery systems target specific therapies are prevailing. Also ER positive drugs for breast cancer are being introduced to the market. Drugs approved for prevention of breast cancer like Raloxifene Hydrochloride, Elvista etc. and drugs approved for the treatment of breast cancer like Abemaciclib, Abraxane, Xeloda, Taxol, Methotrexate etc. have been mentioned in detail with indication, dosing and pricing in our report on US Breast Cancer Drug Market.

US breast cancer drug market has high potency of growth with 42 drugs being commercially available and more than 300 of them being in the clinical pipeline. It is definitive that the market will grow due to the increase in prevalence of breast cancer and large group of geriatric population. Also, it has become a priority for researches and everyone linked to the healthcare system to find a cure for the second most commonly occurring disease. Even if the growth is slow it will increase exponentially in the near future.

Inaccessibility of the absolute treatment has given a wide scope of stage for the improvement of the US breast cancer drug market. Pharmaceutical companies are now concentrating on the improvement of new products which will be cost effective and will also have least side effects. Different organizations are also engaged with the advancement of specific types of molecules and novel therapies. These organizations have adapted the methodologies of the acquisitions, and furthermore propelling of the new products so as to endeavor in this huge and competitive market. Additionally, competition among new market players is likewise expected to expedite the growth for breast cancer drugs market in near future.

1. US - Cancer Incidence and Prevalence

2. US Breast Cancer Market Landscape

2.1 Incidence and Prevalence

2.2 Diagnosis of Breast Cancer

3. US Breast Cancer Drug Market

3.1 Overview US Breast Cancer Drug Market

3.2 Diagnosis and Screening Market Scenario

3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)

4. Forward Looking Developments in Breast Cancer Drug Market

4.1 ER Positive Breast Cancer

4.1.1 CDK4/6 Inhibitors

4.1.2 PI3K Inhibitors

4.1.3 Crizotinib for Lobular Breast Cancer

4.2 HER2-Positive Breast Cancer

4.2.1 Palbociclib and Herceptin (Spain)

4.2.2 Tecentriq - FDA Approval for Breast Cancer

4.3 Triple Negative Breast Cancer

4.3.1 Atezolizumab and Nab-Paclitaxel

4.3.2 Sacituzumab Govitecan

4.3.3 Carboplatin and Docetaxel

5. US - Dosage and Pricing Insight for Drugs Approved for the Prevention of Breast Cancer

5.1 Raloxifene Hydrochloride

5.2 Elvista

5.3 Tamoxifen Citrate

6. US - Dosage and Pricing Insight for Drugs Approved for the Treatment of Breast Cancer

6.1 Abemaciclib

6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

6.3 Ado-Trastuzumab Emtansine

6.4 Afinitor (Everolimus)

6.5 Anastrozole

6.6 Aromasin (Exemestane)

6.7 Xeloda (Capecitabine)

6.8 Docetaxel (Docetaxel Anhydrous)

6.9 Doxorubicin Hydrochloride

6.10 Ellence (Epirubicin Hydrochloride)

6.11 Fluorouracil

6.12 Taxol (Paclitaxel)

6.13 Methotrexate

6.14 Cyclophosphamide

7. US Breast Cancer Drug Market Dynamics

7.1 Market Drivers

7.1.1 Increasing Incidence of Breast Cancer

7.1.2 Research and Development for Novel Drugs

7.1.3 Increase in Healthcare Expenditure and Funding

7.1.4 Increasing Breast Cancer Screening Programs

7.1.5 Rising Consumption of Tobacco and Alcohol

7.2 US Breast Cancer Drug Market Challenges

7.2.1 Pricing Pressure Experienced by the Innovators

7.2.2 High Cost associated with Drug Development and Clinical Trials

7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US - Breast Cancer Drug Market Forecast

8.1 Future Potential of US Breast Cancer Drug Market

8.2 Opportunities for Forthcoming Drug Classes

9. US - Breast Cancer Drug Clinical Pipeline by Company and Phase

9.1 Research

9.2 Preclinical

9.3 Clinical

9.4 Phase-I

9.5 Phase-I/II

9.6 Phase-II

9.7 Phase-II/III

9.8 Phase-III

9.9 Preregistration

9.10 Registered

10. US - Marketed Breast Cancer Drug Clinical Insight by Company

10.1 Afinitor

10.2 LYNPARZA

10.3 Abraxane

10.4 Verzenio

10.5 Kisqali

10.6 Lymphoseek

10.7 Kadcyla

10.8 Ibrance

10.9 Nerlynx

10.10 Soltamox

10.11 Tykerb

10.12 Zoladex

10.13 Omnitarg, Perjeta

10.14 Halaven

10.15 Taxotere

10.16 Other( 27 Drugs Profiles)

11. Competitive Landscape

11.1 Agilent Technologies

11.2 AstraZeneca

11.3 Bayer HealthCare Pharmaceuticals

11.4 Bristol-Myers Squibb

11.5 Eisai Co Ltd

11.6 Eli Lilly

11.7 Novartis

11.8 Onyx Pharmaceuticals

11.9 Orion

11.10 Perrigo

11.11 Pfizer

11.12 Roche

Figure 1-1: US - Estimated New Cancer Cases and Death (Number), 2019

Figure 1-2: US - Estimated New Cancer Cases and Death (Number), 2018

Figure 1-3: US - Estimated New Cancer Cases and Death in Women, (Number), 2019

Figure 1-4: US - Estimated New Cancer Cases and Death in Men (Number), 2019

Figure 1-5: US - Estimated New Cancer Cases and Death in Women (Number), 2018

Figure 1-6: US - Estimated New Cancer Cases and Death in Men (Number), 2018

Figure 1-7: US - Estimated New Cancer Cases in Men by Type (Number), 2019

Figure 1-8: US - Estimated New Cancer Cases in Men by Type (Number), 2018

Figure 1-9: US - Cancer Death Cases in Men by Type (Number), 2019

Figure 1-10: US - Cancer Death Cases in Men by Type (Number), 2018

Figure 1-11: US - Estimated New Cancer Cases in Women by Type (Number), 2019

Figure 1-12: US - Estimated New Cancer Cases in Women by Type (Number), 2018

Figure 1-13: US - Women Death by Cancer Type (Number), 2019

Figure 1-14: US - Women Death by Cancer Type (Number), 2018

Figure 2-1: US - Breast Cancer Cases in Women (Number), 2019

Figure 2-2: US - Invasive Breast Cancer Cases in Women and Men (Number), 2019

Figure 2-3: US - Risk of Developing Breast Cancer in Women by BRCA Genes (%), April’ 2019

Figure 2-4: US - Risk of Developing Breast Cancer in Women and Men by BRCA2 (%), April’ 2019

Figure 2-5: US - Genetic and Epigenetic Breast Cancer Prevalence in Women (%), April’ 2019

Figure 2-6: US - Estimated New Breast Cancer Cases and Death (Number), 2019

Figure 2-7: US - Estimated New Breast Cancer Cases and Death in Women (Number), 2019

Figure 2-8: US - Estimated New Breast Cancer Cases and Death in Men, (Number), 2019

Figure 2-9: Global - Breast Cancer Occurance due to Genetic Abnormalities (Parents and Aging)

Figure 2-10: Procedures for Diagnosis of Breast Cancer

Figure 3-1: Different Screening Tests available for Breast Cancer

Figure 3-2: US Breast Cancer Clinical Pipeline By Phase (%), 2019 till 2025

Figure 3-3: US Breast Cancer Clinical Pipeline By Phase (Number), 2019 till 2025

Figure 3-4: US - Breast Cancer Clinical Pipeline By Mechanism of Action (%), 2019 till 2025

Figure 3-5: US - Breast Cancer Clinical Pipeline By Drug Class (%), 2019 till 2025

Figure 3-6: US - Breast Cancer Clinical Pipeline By Company (%), 2019 till 2025

Figure 3-7: US - Breast Cancer Clinical Pipeline By Patient Segment (%), 2019 till 2025

Figure 4-1: Ongoing Different Research Areas of Breast Cancer

Figure 5-1: Raloxifene Hydrochloride - Dosage for Osteoporosis and Breast Cancer, One Tablet Daily (Milligram)

Figure 5-2: Raloxifene Hydrochloride - Price per Tablet by Pack Size (US$/Tablet), April’ 2019

Figure 5-3: Raloxifene Hydrochloride - Price per Pack Size (US$/Pack) April’ 2019

Figure 5-4: Elvista - Dosage for Osteoporosis and Breast Cancer, One Tablet Daily (Milligram)

Figure 5-5: Elvista - Price per Tablet by Pack Size (US$/Tablet), April’ 2019

Figure 5-6: Elvista - Price per Pack by Size (US$/Pack), April’ 2019

Figure 5-7: Tamoxifen citrate - Price per Tablet by Pack Size for 10 Milligram Dose (US$/Tablet), April’ 2019

Figure 5-8: Tamoxifen citrate - Cost of Different Quantities for 10 Milligram Dose (US$/Pack), April’ 2019

Figure 5-9: Tamoxifen citrate - Cost of Different Quantities for 20 Milligram Dose (US$/Tablet), April’ 2019

Figure 5-10: Tamoxifen citrate - Cost of Different Quantities for 20 Milligram Dose (US$/Pack), April’ 2019

Figure 6-1: Verzenio (Abemaciclib) - Recommended Dosage (Combination Therapy vs Monotherapy) in Milligrams

Figure 6 2: Verzenio - Cost (US$)per Tablet across various Doses (Milligram), April’2019

Figure 6-3: Abraxene - Dosage via Intravenously (Milligram) and Cost for 1 powder of Injection (Milligram), (US$), April’ 2019

Figure 6-4: Kadcyla (Ado-Trastuzumab Emtansine) - Cost per Unit (Milligram) of 1 powder (US$/Injection), April’ 2019

Figure 6-5: Afinitor (Everolimus) - Cost of Different Units (Milligram) Dose (US$/Tablet), April’ 2019

Figure 6-6: Afinitor (Everolimus) - Cost of Different Units (Milligram) Dose (US$/Pack), April’ 2019

Figure 6-7: Anastrozole - Cost of Different Quantities for 1 Milligram Dose (US$/Tablet), April’ 2019

Figure 6-8: Anastrozole - Cost of Different Quantities for 1 Milligram Dose (US$/Pack), April’ 2019

Figure 6-9: Exemestane: Cost as per Quantity for 25 Milligram Dose Per Tablet vs Pack, (US$), April’ 2019

Figure 6-10: Xeloda (Capecitabine) - Dosage as per Oral Intake (Milligram per Metre Square)

Figure 6-11: Xeloda - Cost of Different Quantities for 150 and 500 Milligram Dose (US$/Unit), April’ 2019

Figure 6-12: Xeloda - Cost of Different Quantities for 150 and 500 Milligram Dose (US$/Pack), April’ 2019

Figure 6-13: Docetaxel (Docetaxel Anhydrous) - Minimum and Maximum Dosage for Metaststic Breast Cancer (Milligram per Metre Square)

Figure 6-14: Docetaxel (Docetaxel Anhydrous) - Dosage for Node-Positive Breast Cancer (Milligram per Metre Square), Administered with Doxorubicin and Cyclophosphamide

Figure 6-15: Docetaxel - Price per Unit for Different Quantity (Millilitre) of 10 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-16: Docetaxel - Price per Pack for Different Quantity (Millilitre) of 10 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-17: Docetaxel - Price per Unit for Different Quantity (Millilitre) of 20 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-18: Docetaxel - Price per Pack for Different Quantity (Millilitre) of 20 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-19: Doxorubicin Hydrochloride - Price per Unit for Different Quantities of 2 Milligram per Millilitre Dose (US$), April’ 2019

Figure 6-20: Doxorubicin Hydrochloride - Price per Pack for Different Quantities of 2 Milligram per Millilitre Dose (US$), April’ 2019

Figure 6-21: Epirubicin - Price per Unit for Different Supply (Millilitre) of 2 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-22: Epirubicin - Price per Pack for Different Supply (Millilitre) of 2 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-23: Fluorouracil - Price per Unit for Different Supply (Millilitre) of 50 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-24: Fluorouracil - Price per Pack for Different Supply (Millilitre) of 50 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-25: Paclitaxel - Recommended v/s Adjusted Dosage (Milligram per Metre Square) intravenously

Figure 6-26: Taxol (Paclitaxel) - Price per Unit for Supply (Millilitre) of 6 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-27: Taxol (Paclitaxel) - Price per Pack for Supply (Millilitre) of 6 Milligram per Millilitre Intravenous Solution (US$), April’ 2019

Figure 6-28: Methotrexate - Price per Unit for Injectable Powder (Gram) and Injectable Solution (Milligram per Millilitre) for Injection (US$), April’ 2019

Figure 6-29: Methotrexate - Price per Tablet for Supply of 2.5 Milligram Dose (US$), April’ 2019

Figure 6-30: Methotrexate - Price per Pack for Supply of 2.5 Milligram Dose (US$), April’ 2019

Figure 6-31: Cyclophosphamide - Price per Unit for Supply of 1 Gram, 2 Gram and 5Milligram Dose for 1 Powder of Injection (US$), April’ 2019

Figure 6-32: Cyclophosphamide - Price per Capsule for Supply of 25 and 50 Milligram Dose (US$), April’ 2019

Figure 6-33: Cyclophosphamide - Price per Pack (100) for Supply of 25 and 50 Milligram Dose (US$), April’ 2019

Figure 7-1: Drivers of Breast Cancer Drug Market

Figure 7-2: US - Estimation of Newly Diagnosed Cancers in Women, April’ 2019

Figure 7-3: Challenges of Breast Cancer Drug Market

Figure 8-1: US - Breast Cancer Drug Market Opportunity (US$ Billion), 2019 - 2025

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights:

US Breast Cancer Drug Market Opportunity: US$ 20 Billion

US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment

US Breast Cancer Marketed Drugs: 42 Drugs

US Breast Cancer Drug Clinical Pipeline: 317 Drugs

Dosage and Pricing Insight for Preventive and Treatment Drugs

US Breast Cancer Drug Market Dynamics

1. US - Cancer Incidence and Prevalence

2. US Breast Cancer Market Landscape

2.1 Incidence and Prevalence

2.2 Diagnosis of Breast Cancer

3. US Breast Cancer Drug Market

3.1 Overview US Breast Cancer Drug Market

3.2 Diagnosis and Screening Market Scenario

3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)

4. Forward Looking Developments in Breast Cancer Drug Market

4.1 ER Positive Breast Cancer

4.1.1 CDK4/6 Inhibitors

4.1.2 PI3K Inhibitors

4.1.3 Crizotinib for Lobular Breast Cancer

4.2 HER2-Positive Breast Cancer

4.2.1 Palbociclib and Herceptin (Spain)

4.2.2 Tecentriq - FDA Approval for Breast Cancer

4.3 Triple Negative Breast Cancer

4.3.1 Atezolizumab and Nab-Paclitaxel

4.3.2 Sacituzumab Govitecan

4.3.3 Carboplatin and Docetaxel

5. US - Dosage and Pricing Insight for Drugs Approved for the Prevention of Breast Cancer

5.1 Raloxifene Hydrochloride

5.2 Elvista

5.3 Tamoxifen Citrate

6. US - Dosage and Pricing Insight for Drugs Approved for the Treatment of Breast Cancer

6.1 Abemaciclib

6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

6.3 Ado-Trastuzumab Emtansine

6.4 Afinitor (Everolimus)

6.5 Anastrozole

6.6 Aromasin (Exemestane)

6.7 Xeloda (Capecitabine)

6.8 Docetaxel (Docetaxel Anhydrous)

6.9 Doxorubicin Hydrochloride

6.10 Ellence (Epirubicin Hydrochloride)

6.11 Fluorouracil

6.12 Taxol (Paclitaxel)

6.13 Methotrexate

6.14 Cyclophosphamide

7. US Breast Cancer Drug Market Dynamics

7.1 Market Drivers

7.1.1 Increasing Incidence of Breast Cancer

7.1.2 Research and Development for Novel Drugs

7.1.3 Increase in Healthcare Expenditure and Funding

7.1.4 Increasing Breast Cancer Screening Programs

7.1.5 Rising Consumption of Tobacco and Alcohol

7.2 US Breast Cancer Drug Market Challenges

7.2.1 Pricing Pressure Experienced by the Innovators

7.2.2 High Cost associated with Drug Development and Clinical Trials

7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US - Breast Cancer Drug Market Forecast

8.1 Future Potential of US Breast Cancer Drug Market

8.2 Opportunities for Forthcoming Drug Classes

9. US - Breast Cancer Drug Clinical Pipeline by Company and Phase

9.1 Research

9.2 Preclinical

9.3 Clinical

9.4 Phase-I

9.5 Phase-I/II

9.6 Phase-II

9.7 Phase-II/III

9.8 Phase-III

9.9 Preregistration

9.10 Registered

10. US - Marketed Breast Cancer Drug Clinical Insight by Company

10.1 Afinitor

10.2 LYNPARZA

10.3 Abraxane

10.4 Verzenio

10.5 Kisqali

10.6 Lymphoseek